Block Drug's BC Powder
Executive Summary
Company will met with FDA at a May 19 OTC "feedback meeting" to discuss contribution of the adjuvant salicylamide to Block's analgesic product, which also contains aspirin and caffeine. Salicylamide, along with other adjuvants, are classified as Category III in analgesic TFM. Block gave agency a pharmacokinetic study to show that ingredient increases the plasma concentration of aspirin, and a protocol for a study on salicylamide's role in reducing pain to support moving the ingredient to Category I. The meeting will be held at 2:30 in Conference Room C of FDA's Parklawn Building.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.